Selective Blockade of Endothelin-B Receptors Exacerbates Ischemic Brain Damage in the Rat

Abstract

Our results suggest that the ET(B) antagonist BQ-788 induces deleterious effects that are mediated by the reduction of residual blood flow after ischemia and argue that the optimal therapeutic strategy in stroke would be to target the use of selective ET(A) antagonists and not mixed ET(A)/ET(B) antagonists.